TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update November 13, 2025
Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated NSCLC November 10, 2025
